Seres Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing live biotherapeutics to treat serious diseases by modulating the human microbiome. The company creates therapies using rationally selected live bacteria consortia and has a development pipeline that includes its lead product, VOWST™, which is the first FDA-approved oral live biotherapeutic. Seres serves various healthcare markets and operates primarily in the United States, leveraging its expertise in drug development and microbiome science to advance its therapeutic offerings.
- Website
- www.serestherapeutics.com
- Issuer profile
- All listings